PF-05387552

New Drug Approvals

str1

str1

STR3

CID 50992153.png

PF-05387552

IRAK4

CAS 1604034-71-0
C25 H27 N5 O2
11H-​Indolo[3,​2-​c]​quinoline-​9-​carbonitrile, 2-​methoxy-​3-​[3-​(4-​methyl-​1-​piperazinyl)​propoxy]​-
2-methoxy-3-[3-(4-methylpiperazin-1-yl)propoxy]-11H-indolo[3,2-c]quinoline-9-carbonitrile
Molecular Weight429.51
Molecular Formula: C25H27N5O2
Molecular Weight: 429.51418 g/mol

Synthesis

str1

PAPER

Bioorganic & Medicinal Chemistry Letters (2014), 24(9), 2066-2072

Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4

 aPfizer Global R&D, 445 Eastern Point Rd., Groton…

View original post 304 more words

Debiopharm and Aurigene dual c-src / jak inhibitors

New Drug Approvals

SCHEMBL2237115.pngSTR3str4

Debio 1142

Jak2 tyrosine kinase inhibitor; Src tyrosine kinase inhibitor

N-[4-methyl-3-[2-[4-(4-methylpiperazin-1-yl)anilino]-5-oxo-7,8-dihydropyrido[4,3-d]pyrimidin-6-yl]phenyl]-3-(trifluoromethyl)benzamide

Molecular Formula: C33H32F3N7O2
Molecular Weight: 615.64809 g/mol
1332328-01-4
Benzamide, N-​[3-​[7,​8-​dihydro-​2-​[[4-​(4-​methyl-​1-​piperazinyl)​phenyl]​amino]​-​5-​oxopyrido[4,​3-​d]​pyrimidin-​6(5H)​-​yl]​-​4-​methylphenyl]​-​3-​(trifluoromethyl)​-

Debiopharm S.A., Aurigene Discovery Technologies Ltd.

ALLISTER Andrès MC, Maximilien Murone,Saumitra Sengupta, Shankar Jayaram Shetty

https://www.google.co.in/patents/WO2011101806A1?cl=en

Bicyclic compounds and their uses as dual c-src / jak inhibitors

STR3

Apr. 14 /PR Newswire/ –Debiopharm and Aurigene Sign Agreement for the Development and Commercialisation of Debio 1142, a Novel Inhibitor of an Undisclosed Oncology Pathway

LAUSANNE, Switzerland and BANGALORE, India, April 14, 2011 /PRNewswire/ — Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based drug discovery company, signed on March 23, 2011 an option and exclusive worldwide license agreement concerning the development and commercialisation of…

View original post 433 more words

I (Anthony Crasto) am Editorial Board member for our Journal of Analytical & Pharmaceutical Research

New Drug Approvals

str1str2
Dear Readers
I am on  editorial board ……… Editorial Board member for our Journal of Analytical & Pharmaceutical Research………http://medcraveonline.com/JAPLR/editorial-board

This is possible with your cooperation and support

SOME PAPERS

read…….http://medcraveonline.com/JAPLR/JAPLR-02-00010.pdf
http://medcraveonline.com/JAPLR/JAPLR-02-00011.pdf

Tackling the Challenges with Poorly Soluble Drugs
http://medcraveonline.com/JAPLR/JAPLR-01-00001.pdf

View original post